ABC Content Board

The abc of trending content

Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

Co-Diagnostics CEO Dwight Egan noted, “We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring.”

Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends both to manufacture and sell reagents used for diagnostic tests, has completed its initial public offering and started trading on the NASDAQ Capital Market.

Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected by five granted or pending US patents, as well as by certain trade secrets, which allow it to set its prices lower than comparable tests in the market place.

The Company intends to use the proceeds from the recent offering to expand existing operations and the availability of its products. The tests for tuberculosis, hepatitis B and C, malaria, HIV and Zika virus will be among those initially developed and marketed by the Company. Proceeds may also be used in the Company’s pursuit of regulatory approvals. Co-Diagnostics intends to license certain technologies to research institutions, as well as to CLIA laboratories interested in using them in the creation of laboratory developed tests (LDTs).

Co-Diagnostics CEO Dwight Egan noted, “We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Co-Diagnostics has the utmost confidence in the uniqueness of our intellectual property. We believe that this IP, combined with our hard-working staff and associates, low development costs and the exceptional partner relationships we have been cultivating over the last few years will be the…

Read the full article from the Source…

Back to Top